

Supplemental Information

SUPPLEMENTAL TABLE 7 Summary of the Included Trials and Number of Participants by Indication and Study Design

Condition	No. Studies	Randomized, Double-Blind, Placebo-Controlled	Randomized, Open-Label	Open-Label	Longitudinal Observational	Retrospective
Intraabdominal infection	3	—	260	200	105	—
Herpes simplex virus (presumed or suspected)	2	—	—	32	—	49
Antiepileptic drugs and obesity	1	—	—	117	—	—
Indication for Gram-positive coverage	2	—	—	22	—	68
Anesthetic or analgesic	1	—	—	126	—	—
Spasticity associated with cerebral palsy	1	—	—	64	—	—
Medication use in lactating women	1	—	—	872	—	—
Single-ventricle congenital heart disease	1	—	—	13	—	—
Indication for a loop diuretic	2	80	—	—	—	679
Antihypertensive in renal transplant	1	—	—	29	—	—
Sickle cell anemia	1	—	—	42	—	—
Indication for a antipsychotic medication	1	—	—	—	356	—
Bipolar I disorder	1	153	—	—	—	—
Status epilepticus	1	—	310	—	—	—
Indication for anaerobic and/or protozoal coverage	1	—	—	24	—	—
Opiate withdrawal	1	—	—	26	—	—
GERD and obesity	1	—	—	48	—	—
General pediatrics: drug study	2	—	—	3553	—	—
General pediatrics: device study	3	—	—	3247	—	—
Pulmonary hypertension	1	—	—	34	—	—
Bronchopulmonary dysplasia	1	50	—	—	—	—
Intravenous hypertension control	1	65	—	—	—	—
Sodium nitroprusside use	1	—	—	—	—	126
Indication for antistaphylococcal coverage	1	—	—	63	—	—
Infantile hemangioma	1	105	—	—	—	—

GERD, gastroesophageal reflux disease; —, not applicable.